Keynote-522 Updates: Pembrolizumab Plus Neoadjuvant Chemotherapy In Early Triple-Negative Breast...

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

Exploratory analysis of KEYNOTE-522: EFS after neoadjuvant pembro + chemo Vs chemo for early TNBC

Remaining questions on the use of neoadjuvant pembrolizumab in early TNBC following KEYNOTE-522

KEYNOTE-522: EFS sensitivity & subgroup analyses

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breas...

Update on Keynote 522, the current standard of care for triple negative breast cancer.

OncBrothers: Practice-Changing Cancer Discussions

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer

Targeted Oncology

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC

A post hoc analysis of adjuvant radiation therapy in the KEYNOTE-522 study

KEYNOTE-522: Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs place...

Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OS

Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBC

Neoadjuvant chemoimmunotherapy: KEYNOTE-522, I-SPY & more

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBC

The case for neoadjuvant pembrolizumab in TNBC

KEYNOTE-522: Immune therapy and chemotherapy in patients with early triple negative breast cancer

GS1-01: "Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant..."

San Antonio Breast Cancer Symposium